Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

MustGrow Biologics

CNSX:MGRO
Snowflake Description

Imperfect balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MGRO
CNSX
CA$15M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

MustGrow Biologics Corp., an agriculture bio-tech company, focuses on providing natural science-based biological solutions for high value crops. The last earnings update was 124 days ago. More info.


Add to Portfolio Compare Print
  • MustGrow Biologics has significant price volatility in the past 3 months.
MGRO Share Price and Events
7 Day Returns
25%
CNSX:MGRO
3.5%
CA Biotechs
4.5%
CA Market
1 Year Returns
-
CNSX:MGRO
-34.5%
CA Biotechs
-24.5%
CA Market
MGRO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MustGrow Biologics (MGRO) 25% -20% -21.6% - - -
CA Biotechs 3.5% -12.9% -7.4% -34.5% -0.3% -40.7%
CA Market 4.5% -20.1% -24.9% -24.5% -22.2% -16.5%
1 Year Return vs Industry and Market
  • No trading data on MGRO.
  • No trading data on MGRO.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is MustGrow Biologics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether MustGrow Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MustGrow Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MustGrow Biologics. This is due to cash flow or dividend data being unavailable. The share price is CA$0.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MustGrow Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MustGrow Biologics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:MGRO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CAD CA$-0.05
CNSX:MGRO Share Price ** CNSX (2020-03-31) in CAD CA$0.4
North America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 16.23x
Canada Market PE Ratio Median Figure of 498 Publicly-Listed Companies 10.3x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MustGrow Biologics.

CNSX:MGRO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:MGRO Share Price ÷ EPS (both in CAD)

= 0.4 ÷ -0.05

-7.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MustGrow Biologics is loss making, we can't compare its value to the North America Biotechs industry average.
  • MustGrow Biologics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does MustGrow Biologics's expected growth come at a high price?
Raw Data
CNSX:MGRO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.84x
Canada Market PEG Ratio Median Figure of 235 Publicly-Listed Companies 0.7x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MustGrow Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MustGrow Biologics's assets?
Raw Data
CNSX:MGRO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CAD CA$-0.01
CNSX:MGRO Share Price * CNSX (2020-03-31) in CAD CA$0.4
Canada Biotechs Industry PB Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 3.21x
Canada Market PB Ratio Median Figure of 2,349 Publicly-Listed Companies 0.99x
CNSX:MGRO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:MGRO Share Price ÷ Book Value per Share (both in CAD)

= 0.4 ÷ -0.01

-35.83x

* Primary Listing of MustGrow Biologics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MustGrow Biologics has negative assets, we can't compare the value of its assets to the CA Biotechs industry average.

Next steps:

  1. Take a look at our analysis of MGRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MustGrow Biologics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess MustGrow Biologics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MustGrow Biologics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MustGrow Biologics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MustGrow Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MustGrow Biologics expected to grow at an attractive rate?
  • Unable to compare MustGrow Biologics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MustGrow Biologics's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare MustGrow Biologics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:MGRO Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 34.4%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 52.7%
Canada Market Earnings Growth Rate Market Cap Weighted Average 7.4%
Canada Market Revenue Growth Rate Market Cap Weighted Average 3.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:MGRO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:MGRO Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-09-30 0 -1 -1
2019-06-30 0 -1 -1
2019-03-31 0 -1 -1
2018-12-31 0 -1 -2
2018-09-30 0 -1 -2
2018-06-30 0 -1 -1
2018-03-31 0 -1 -1
2017-12-31 0 0 0
2016-12-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MustGrow Biologics is high growth as no earnings estimate data is available.
  • Unable to determine if MustGrow Biologics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:MGRO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from MustGrow Biologics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MGRO Past Financials Data
Date (Data in CAD Millions) EPS *
2019-09-30 -0.05
2019-06-30 -0.05
2019-03-31 -0.04
2018-12-31 -0.09
2018-09-30 -0.10
2018-06-30 -0.06
2018-03-31 -0.06
2017-12-31 -0.02
2016-12-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MustGrow Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of MGRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. MustGrow Biologics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. MustGrow Biologics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess MustGrow Biologics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MustGrow Biologics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MustGrow Biologics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MustGrow Biologics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MustGrow Biologics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare MustGrow Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MustGrow Biologics's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MustGrow Biologics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MustGrow Biologics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MGRO Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.00 -1.31 1.12 0.07
2019-06-30 0.00 -1.13 1.02 0.05
2019-03-31 0.00 -0.97 0.86 0.02
2018-12-31 0.00 -1.89 0.89 0.01
2018-09-30 0.00 -1.72 0.67 0.00
2018-06-30 0.00 -1.49 0.54 0.00
2018-03-31 0.00 -1.38 0.50 0.00
2017-12-31 0.00 -0.20 0.22 0.00
2016-12-31 0.11 -0.17 0.24
2015-12-31 0.01 -0.58 0.49

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MustGrow Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if MustGrow Biologics has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MustGrow Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MustGrow Biologics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MustGrow Biologics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MustGrow Biologics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MustGrow Biologics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MustGrow Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MustGrow Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MustGrow Biologics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • MustGrow Biologics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MustGrow Biologics Company Filings, last reported 6 months ago.

CNSX:MGRO Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -0.28 0.74 0.77
2019-06-30 0.10 0.73 1.12
2019-03-31 0.41 0.72 1.40
2018-12-31 -0.49 0.71 0.51
2018-09-30 -0.32 0.70 0.71
2018-06-30 -0.16 0.76 0.92
2018-03-31 0.00 0.76 1.08
2017-12-31 -1.21 0.84 0.01
2016-12-31 -1.02 0.76 0.05
2015-12-31 -0.85 0.75 0.13
  • MustGrow Biologics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if MustGrow Biologics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MustGrow Biologics has less than a year of cash runway based on current free cash flow.
  • MustGrow Biologics has less than a year of cash runway if free cash flow continues to grow at historical rates of 29.5% each year.
X
Financial health checks
We assess MustGrow Biologics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MustGrow Biologics has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MustGrow Biologics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MustGrow Biologics dividends.
If you bought CA$2,000 of MustGrow Biologics shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MustGrow Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MustGrow Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:MGRO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 66 Stocks 2.2%
Canada Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 4.8%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.3%
Canada Bottom 25% Dividend Yield 25th Percentile 2.7%
Canada Top 25% Dividend Yield 75th Percentile 8.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MustGrow Biologics has not reported any payouts.
  • Unable to verify if MustGrow Biologics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MustGrow Biologics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MustGrow Biologics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MustGrow Biologics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MustGrow Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MustGrow Biologics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MustGrow Biologics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Corey Giasson
COMPENSATION CA$128,000
AGE 41
TENURE AS CEO 2.1 years
CEO Bio

Mr. Corey J. Giasson, MBA, B.Sc., serves as President at MustGrow Biologics Corp. and serves as its Chief Executive Officer and Director since March 15, 2018. Mr. Giasson had been the Chief Financial Officer of MustGrow Biologics Corp. since March 15, 2018 till December 17, 2018. He served as the President and Chief Executive Officer of Rallyemont Energy Inc. Mr. Giasson served as the Chief Executive Officer, President and Promoter of Kenna Capital Corp. until April 2012. Mr. Giasson was an independent consultant of PanWestern Energy Inc., Infrastructure Materials Corp., and Anglo Potash Ltd. He served as a Vice President of Business Development and Investor Relations at Anglo Potash Limited (also known as Anglo Minerals Ltd). since May 1, 2007. Mr. Giasson was employed by PotashCorp, the world's largest potash producer in Saskatoon, Saskatchewan, where he held the title of Manager, Market Research. Mr. Giasson was employed for three years as a business analyst at an accounting and business advisory firm where he assisted in consulting primary and secondary agriculture producers. He served as a Director of Rallyemont Energy Inc. He served as a Director of Kenna Resources Corp. from September 25, 2009 to July 23, 2014. Mr. Giasson holds an MBA and a B.Sc. in Agriculture Economics from the University of Saskatchewan.

CEO Compensation
  • Insufficient data for Corey to compare compensation growth.
  • Corey's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the MustGrow Biologics management team in years:

1.6
Average Tenure
  • The average tenure for the MustGrow Biologics management team is less than 2 years, this suggests a new team.
Management Team

Corey Giasson

TITLE
President
COMPENSATION
CA$128K
AGE
41
TENURE
2.1 yrs

Todd Lahti

TITLE
CFO & Corporate Secretary
AGE
53
TENURE
1.3 yrs

Colin Bletsky

TITLE
COO & Director
COMPENSATION
CA$40K
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the MustGrow Biologics board of directors in years:

1.9
Average Tenure
41
Average Age
  • The average tenure for the MustGrow Biologics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Brad Munro

TITLE
Independent Chairman

Corey Giasson

TITLE
President
COMPENSATION
CA$128K
AGE
41
TENURE
2.1 yrs

Colin Bletsky

TITLE
COO & Director
COMPENSATION
CA$40K
TENURE
2.1 yrs

Tom Flow

TITLE
Independent Director
AGE
41
TENURE
1.9 yrs

Matt Kowalski

TITLE
Independent Director
TENURE
1.9 yrs

Brian Quigley

TITLE
Director
AGE
45
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by MustGrow Biologics individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
05. Feb 20 Buy Bradley Munro Individual 04. Feb 20 04. Feb 20 40,000 CA$0.50 CA$20,000
11. Dec 19 Buy Colin Bletsky Individual 10. Dec 19 10. Dec 19 380,000 CA$0.35 CA$133,000
11. Dec 19 Buy Brian Quigley Individual 10. Dec 19 10. Dec 19 286,000 CA$0.35 CA$100,100
10. Dec 19 Buy Corey Giasson Individual 10. Dec 19 10. Dec 19 284,800 CA$0.35 CA$99,680
10. Dec 19 Buy Todd Lahti Individual 10. Dec 19 10. Dec 19 129,357 CA$0.35 CA$45,275
28. Oct 19 Buy Colin Bletsky Individual 28. Oct 19 28. Oct 19 50,000 CA$0.30 CA$14,708
27. Sep 19 Buy Colin Bletsky Individual 27. Sep 19 27. Sep 19 35,000 CA$0.31 CA$10,210
17. Oct 19 Buy Corey Giasson Individual 10. Oct 19 10. Oct 19 4,000 CA$0.28 CA$1,120
11. Oct 19 Buy Colin Bletsky Individual 11. Oct 19 11. Oct 19 15,000 CA$0.29 CA$4,350
08. Oct 19 Buy Corey Giasson Individual 08. Oct 19 08. Oct 19 23,000 CA$0.29 CA$6,460
02. Oct 19 Buy Corey Giasson Individual 01. Oct 19 01. Oct 19 28,000 CA$0.29 CA$8,120
11. Sep 19 Buy Corey Giasson Individual 11. Sep 19 11. Sep 19 50,000 CA$0.31 CA$15,750
10. Sep 19 Buy Colin Bletsky Individual 10. Sep 19 10. Sep 19 25,000 CA$0.32 CA$7,825
10. Sep 19 Buy Corey Giasson Individual 10. Sep 19 10. Sep 19 50,000 CA$0.32 CA$15,525
05. Sep 19 Buy Corey Giasson Individual 04. Sep 19 04. Sep 19 5,000 CA$0.30 CA$1,500
04. Sep 19 Buy Colin Bletsky Individual 04. Sep 19 04. Sep 19 25,000 CA$0.31 CA$7,650
X
Management checks
We assess MustGrow Biologics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MustGrow Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is MustGrow Biologics (CNSX:MGRO) A Risky Investment?

CNSX:MGRO Historical Debt, July 31st 2019 How Strong Is MustGrow Biologics's Balance Sheet? … This surplus suggests that MustGrow Biologics has a conservative balance sheet, and could probably eliminate its debt without much difficulty. … Overall, its balance sheet doesn't seem overly risky, at the moment, but we're always cautious until we see the positive free cash flow.

Simply Wall St -

Company Info

Description

MustGrow Biologics Corp., an agriculture bio-tech company, focuses on providing natural science-based biological solutions for high value crops. Its products include pre-plant bio-pesticides for fruits and vegetables, as well as products for cannabis and hemp industries. The company is headquartered in Saskatoon, Canada.

Details
Name: MustGrow Biologics Corp.
MGRO
Exchange: CNSX
Founded:
CA$14,877,053
37,192,634
Website: http://www.mustgrow.ca
Address: MustGrow Biologics Corp.
1005 - 201 1st Avenue South,
Saskatoon,
Saskatchewan, S7K 1J5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX MGRO Common Shares Canadian National Stock Exchange CA CAD 10. Jul 2019
DB 0C0 Common Shares Deutsche Boerse AG DE EUR 10. Jul 2019
Number of employees
Current staff
Staff numbers
0
MustGrow Biologics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/01 01:12
End of day share price update: 2020/03/31 00:00
Last earnings filing: 2019/11/29
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.